UK debates asbestos-related diseases compensation, heralds a new healthcare focus?
This article was originally published in Clinica
The UK parliament took a further step towards better addressing the needs of asbestos-related diseases (ARDs), with further debate of draft legislation on compensating pleural plaques and asbestosis. The issue of compensation is relevant to the development of medical research and healthcare in this area, in that a greater willingness to recognise exposure will impact on assessing and meeting healthcare demand.
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.